---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013711"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2025-06-05T23:59:59+00:00"
generated_at: "2026-05-19T22:54:22.062169+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Telomir-1 preclinical study in Werner Syndrome model shows 100% survival, reverses epigenetic aging

## Summary
- Oral Telomir-1 restored healthy DNA methylation at two CpG island regions, resetting the epigenetic clock.
- Telomere length increased beyond levels seen in healthy controls.
- Full reversal of muscle and body weight loss in the Werner Syndrome animal model.
- 100% survival in Telomir-1-treated animals vs 15% mortality in untreated controls.
- Oxidative stress markers reduced by up to 50%.

## SEC filing metadata
- accession: 0001641172-25-013711
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2025-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000164117225013711/0001641172-25-013711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000164117225013711/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013711
- JSON: https://secwatch.observer/filing/0001641172-25-013711.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.